-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2190 Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Hematology Disease Topics & Pathways:
Adult, Acute Myeloid Malignancies, AML, Diseases, Biological therapies, Myeloid Malignancies, Study Population, Human, Transplantation (Allogeneic and Autologous)
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Arnon Nagler, MD1, Allain-Thibeault Ferhat2*, Didier Blaise, MD, PhD3, Yener Koc, MD4, Emanuele Angelucci, MD5, Alessandro Busca, MD6*, Jiri Pavlu, MD, FRCPath, MRCP7, Stefania Bramanti8*, Maija Itäla-remes, MD, PhD9*, Maria Aranzazu Bermudez Rodriguez10*, Jan Vydra, MD11*, Alexander Kulagin, MD, PhD12*, Ali Bazarbachi, MD, PhD13, Bipin N. Savani, MD14, Fabio Ciceri, MD15* and Mohamad Mohty, MD, PhD16,17

1Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv, Israel
2EBMT Statistical Unit, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
3Program of Transplant and cellular immunotherapy, Department of Hematology, Institut Paoli Calmettes, Marseille, France
4MEDICAL PARK HOSPITALS, Beylikduzu, Istanbul, TUR
5IRCCS Ospedale Policlinico San Martino, Genova, Italy
6SS Trapianto di Cellule Staminali, Torino, Italy
7Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
8Bone Marrow Transplantation and Cell Therapy Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
9Department of Clinical Haematology and Stem Cell Transplant Unit, University Hospital Turku, Turku, Finland
10Hospital U. Marqués de Valdecilla, SANTANDER, Spain
11Institute of Hematology and Blood Transfusion, Prague 10, CZE
12RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation
13Department of Hematology and bone marrow transplant, American University of Beyrouth, Beyrouth, Lebanon
14Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
15Ospedale San Raffaele, Haematology and BMT, Milano, Italy
16Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
17Acute Leukemia Working Party, Paris Study office, European Society for Blood and Marrow Transplantation, Paris, France

Background: Secondary acute myeloid leukemia (sAML) is a distinct type of high risk AML with inferior outcome. Haploidentical stem cell transplantation (HaploSCT) with post-transplant cyclophosphamide (PTCy) is an encouraging therapeutic option for sAML (J Hematol Oncol 2023, 16(1):106). However, in the context of sAML, it is still unknown whether peripheral blood (PB) or bone marrow (BM) is the best graft source. In view of the high relapse incidence (RI) accompanying sAML, PB grafts, potentially with a stronger graft-versus-leukemia (GVL) effect, may be beneficial.

Methods: The study aim was to compare PB vs. BM as a graft source for HaploSCT with PTCy performed between 2010 and 2022 in patients (pts) with sAML in first complete remission (CR1). Statistical tests included a multivariable analysis (MVA) using a Cox proportional-hazards regression model for main outcomes.

Results: A total of 554 pts were included, 418 with PB and 136 with BM grafts. Median follow-up was 2.8 years (interquartile range [2.5 – 3]) and 4.1 years [3.4 - 5.3], respectively. The median year of the transplant was 2019 (range, 2011-2021) in pts with PB and 2017 (range, 2010-2022) in those with BM grafts (p<0.001). Pts with PB grafts were older, with a median age of 61.7 (range 19.1-75.6) vs. 59.2 (19.3-75.7) years, (p=0.008). and 60% and 57%, were male, respectively, (p=0.48). In 91% of pts, the antecedent hematological disease was myelodysplastic/myeloproliferative disorder with no difference between the groups. The cytogenetic risk was categorized as intermediate (61% vs. 62%), adverse (38% vs. 37%), and favorable (1% in both) for pts receiving PB vs. BM grafts, respectively (p=0.96) (data missing for 118 pts). Karnofsky performance status (KPS), the frequency of both pt and donor cytomegalovirus (CMV) seropositivity as well as female donor to male pt combination did not differ between the two groups. Time from diagnosis to HaploSCT was significantly shorter for the PB vs. BM cohorts, being 4.8 (range 11.1-17) vs. 5.3 (1.8-16.2) months (p=0.019). A lower percentage of HaploSCT with PB compared to BM grafts received myeloablative conditioning; 39% and 57%, respectively (p<0.001), with thiotepa/busulfan/fludarabine being the most frequent regimen for both groups (38% vs. 69%). PTCy-based graft-versus-host disease (GVHD) prophylaxis was combined with cyclosporine A (CSA)/mycophenolate mofetil in 63% vs. 69% and CSA/tacrolimus in 34% vs. 31% of transplants, respectively. Cumulative incidence of absolute neutrophil count >0.5 x 109/L at day 60 was 94.9% vs. 90.2%, respectively. In MVA acute GVHD grades II-IV, III-IV, and extensive chronic GVHD (cGVHD) did not differ significantly between pts receiving PB vs. BM grafts with a 2-year estimation of 31% vs. 22.2% (hazard ratio [HR]= 1.27; p=0.27), 10.7% vs. 6.9% (HR= 1.41; p=0.37) and 11.2% vs. 7.6% (HR= 1.4; p=0.36), respectively, while total cGVHD 2-year estimation was lower with BM vs. PB grafts with 33.7% vs. 22.9% (HR= 1.41; p=0.02). Other HaploSCT outcomes also did not differ significantly between pts receiving PB vs. BM grafts. The HR for 2-year non-relapse mortality (NRM) was 1.25 (95% CI 0.8-1.94, p=0.326), and for 2-year RI it was 0.85 (95% CI 0.55-1.33, p=0.48). RI was the main cause of death in BM (51% of pts) and NRM in PB transplants (50% of pts). The HRs for 2-year leukemia-free survival (LFS), overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were 1.04 (95% CI 0.76-1.42, p=0.81), 1.00 (95% CI 0.72-1.39, p=0.1) and 1.13 (95% CI 0.85-1.5, p=0.42), respectively. Adverse-risk cytogenetics was a poor prognostic factor for RI, LFS, OS, and GRFS and both higher age (per 10 years) and lower KPS were poor prognostic factors for OS and GRFS. Lower KPS was also a poor prognostic factor for NRM and LFS. Adverse-risk cytogenetics and low intensity conditioning were poor prognostic factors for RI. In addition, age (per 10 years) and female donor to male pt combination were associated with increased risk of total cGVHD.

Conclusions: In this retrospective analysis of HaploSCT with PTCy for sAML in CR1, comparing PB vs. BM grafts, we observed similar transplantation outcomes except for lower incidence of total cGVHD with BM grafts. Notably, HaploSCT was able to rescue ~60% of the pts with this devastating leukemia. We did not observe lower RI with PB grafts, being ~22% at 2 years. Hopefully, with the recently approved novel agents for sAML it will be possible to further improve outcomes.

Disclosures: Angelucci: Sanofi: Honoraria; Vertex: Other: DMC; Menarini: Honoraria, Speakers Bureau; Vifor: Other: DMC; Regeneron: Honoraria; Novartis: Honoraria; BMS: Other: DMC. Bazarbachi: Takeda: Honoraria; Amgen: Honoraria; Caribou: Honoraria; Pfizer: Research Funding; Biologix: Research Funding; Jansen: Honoraria, Research Funding; Roche: Honoraria, Research Funding. Ciceri: ExCellThera: Membership on an entity's Board of Directors or advisory committees. Mohty: Jazz: Consultancy, Honoraria, Research Funding, Speakers Bureau; Stemline Menarini: Honoraria; GSK: Honoraria; Novartis: Honoraria; Takeda: Honoraria; BMS: Consultancy, Honoraria; Pfizer: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen: Honoraria; Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau; Adaptive: Honoraria; MaaT Pharma: Current equity holder in publicly-traded company.

*signifies non-member of ASH